Einsatz von Opioidantagonisten in der abstinenzerhaltenden Behandlung der Opiatabhängigkeit

Suchttherapie

Volumn 5, Issue 2, 2004, Pages 90-93

  Kiefer, F ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

addiction; naltrexone; opiate; Opioid; treatment

Indexed keywords

EID: 3142676961     PISSN: 14399903     EISSN: 1439989X     Source Type: Journal    
DOI: 10.1055/s-2004-813163     Document Type: Article

References (40)

1. Blumberg H. Analgesic properties of the narcotic antagonist EN-2234 A. Pharmacologists 1968; 10: 201
2. Kleber HD, Kosten TR, Gaspari J et al. Nontolerance to the opioid antagonism of naltrexone. Biological Psychiatry 1985; 20: 66–72
3. Ionescu F, Klee W, Katz R. Antagonist potency and receptor binding. Life Sciences 1975; 16: 1973–1974
4. Gonzalez JP, Brogden RN. Naltrexone: A Review of its Pharmacodynamic and Pharmacokinetic Properties and Therapeutic Efficacy in the Management of Opioid Dependence. Drugs 1988; 35: 192–213
5. Kleber HD. Final report: Double-blind, placebo controlled study administered by the National Academy of Sciences, to evaluate the safety and efficacy of the narcotic antagonist unpublished.
6. Verebey K, Volavka J, Mule SJ et al. Naltrexone: Disposition, metabolism and effects after acute and chronic dosing. Clin Pharmacol Ther 1976; 20: 315–328
7. Wikler A. Recent progress in research on the neurophysiological basis of morphine addiction. Am J Psychiatry 1948; 105: 329–338
8. Wikler A. Present status of the concept of drug dependence. Psychol Med 1971; 1: 377–380
9. Wikler A. Dynamics of Drug Dependence. Arch Gen Psychiatry 1973; 28: 611–616
10. Wikler A. The theoretical basis of narcotic addiction treatment with narcotic antagonists. In: Julius D, Renault P. (eds). Narcotic Antagonist: naltrexone. National Institute on Drug Abuse (NIDA) Research Monograph 9. Rockville: Government Printing Office, 1976: 119–122
11. Bradford HA. Interim report on clinic intake and safety data collected from 17 NIDA funded naltrexone centers. In: Julius D, Renault P (eds). Narcotic antagonists: naltrexone. Rockville: NIDA Research Monogramm 1975: 9: 163–171
12. Callahan EJ. Comparison of two naltrexone programmes: naltrexone alone versus naltrexone plus behaviour therapy. In: Julius D, Renault P (eds). Narcotic antagonists: naltrexone. NIDA Research Monograph. Washington DC: Supt of DocsUS Govt Print Off, 1976: 9: 150–157
13. Callahan EJ, Rawson RA, McCleave B et al. The treatment of heroin addiction: Naltrexone alone Int J Addict 1980; 15: 795–807
14. Capone TA. Psychoanalytic and behavioral considerations in antagonist and methadone programs. J Contemp Psychother 1978; 9 (2): 139–150
15. Fram DH, Marmo J, Holden R. Naltrexone treatment - the problem of patient acceptance. J Subst Abuse Treat 1989; 6: 119–122
16. Garcia-Alonso F, Gutierrez M, San L et al. A multicenter study to introduce naltrexone for opiate dependence in Spain. Drug Alcohol Depend 1989; 23 (2): 117–121
17. Greenstein RA, Arndt IC, McLellan AT et al. Naltrexone: A clinical perspective. J Clin Psychiatry 1984; 45: 25–28
18. O'Brien CP, Greenstein RA, Mintz J et al. Clinical experience with naltrexone. Am J Alcohol Abuse 1975; 2: 365–377
19. Rawson RA. Naltrexone and behavior therapy for heroin addiction. In: Krasnegor NA (ed). NIDA Research Monograph 25, US Dept of Health and Human Services. Rockville, 1979: 26–43
20. Resnick RB, Volavka J, Freedman AM et al. Studies of EN-1639A (naltrexone): A new narcotic antagonist. Am J Psychiatry 1974; 131: 646–650
21. Resnick RB, Schuyten-Resnick E, Washton AM. Narcotic antagonists in the treatment of opioid dependence: review and commentary. Compr Psychiatry 1979; 20: 116–125
22. Sideroff SI, Charuvastra VC, Jarvik ME. Craving in heroin addicts maintained on the opiate antagonist naltrexone. Am J Drug Alcohol Abuse 1979; 5: 415–423
23. Tennant FS Jr., Rawson RA, Cohen AJ et al. Clinical experience with naltrexone in suburban opioid addicts. J Clin Psychiatry 1984; 45: 42–45
24. Lopez-Ibor JL. The medical model in the management of heroin dependence. In: Stefanies CN, Rabavilas AD, Soldatos CR. (eds). Classification and Psychopathology; Child Psychiatry; Substance Use. Proc 8th World Congr Psychiatry, Athens, 12 - 19 October 1989, Vol 1. Amsterdam Excerpta Medica, 1990
25. Ochoa E, Arias F, Somoza JC et al. Treatment with naltrexone in opiate dependents: 2 years' follow-up. Actas Luso Esp Neurol Psiquiatr 1992; 20 (5): 215–229
26. Ochoa E, Arias F, Somoza JC et al. Tratamiento con naltrexona en dependientes de opiáceos: dos anos y medio de seguimiento. Arch Neurobiol 1992; 55 (5): 224–227
27. Hollister LE. Clinical evaluation of naltrexone treatment of opiate-dependent individuals. Report on the National Research Council Committee on Clinical Evaluation of Narcotic Antagonists. Arch Gen Psychiatry 1978; 35: 335–340
28. Lerner A, Sigal M, Bacalu A et al. A naltrexone double blind placebo controlled study in Israel. Isr J Psychiatry Relat Sci 1992; 29 (1): 36–43
29. Nowak M. Naltrexon - der Erfahrungsbericht mit einem Opiat-Langzeitantagonisten. Int. Nemexin® (Naltrexon HCl) Symp. Basel, 1994: 25–30
30. San L, Pomarol G, Peri JM et al. Follow-up after six months maintenance period on naltrexone versus placebo in heroin addicts. Br J Addict 1991; 86: 190, 983–990
31. Shufman EN, Porat S, Witztum E et al. The efficacy of naltrexone in preventing reabuse of heroin after detoxification. Biol Psychiatry 1994; 35: 935–945
32. Kleber HD, Kosten TR. Naltrexone Induction: Psychologic and Pharmacologic Strategies. J Clin Psychiatry 1984; 45 (9, Sec. 2): 29–38
33. Kleber HD. Naltrexone. Journal of Substance Abuse Treatment 1985; 2: 117–122
34. Kosten TR, Kleber HD. Strategies to Improve Compliance with Narcotic Antagonists. AM J Drug Alcohol Abuse 1984; 10 (2): 249–266
35. Anton RF, Hogan I, Jalali B et al. Multiple family therapy and naltrexone in the treatment of opiate dependence. Drug and Alcohol Dependence 1981; 8: 157–168
36. Koc J, Poser W. Ambulante Abstinenz-Therapie der Opiatabhängigkeit mit Naltrexon. Suchtmedizinisches Symposium der Deutschen Gesellschaft für Drogen- und Suchtmedizin e. V. (DGDS). Vortrag 9. März 1996
37. Ling W, Wesson DR. Naltrexone treatment for addicted health-care professionals: A collaborative private practice experience. J Clin Psychiatry 1984; 45: 46–48
38. Neto D. Sequential Combined Treatment of Heroin Addicted Patients in Eur Addict Res 1997; 3: 138–145
39. Roth AS, Ostroff RB, Hoffman RE. Naltrexone as a treatment for repetitive self-injurious behaviour: an open-label trial. J Clin Psychiatry 1996; 57(6): 233–237
40. Washton AM, Pottash AC, Gold MS. Naltrexone in addicted business executives and physicians. J Clin Psychiatry 1984; 45: 39–41